The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results

Desort-Henin et al., ECCMID 2023 (results released 1/5/2023), SAIVE, NCT05305560, Jan 2023

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/desorthenin.html

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 106 studies, recognized in 24 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

6,200+ studies for 200+ treatments. c19early.org

Download Meta Analysis

PEP RCT 399 patients in Bulgaria showing significantly lower COVID-19 cases with ivermectin prophylaxis, and significantly lower cases with high viral load. No participant had severe symptoms, required oxygen, or was hospitalized. All patients with COVID-19 were treated with vitamin C and vitamin D.

This trial makes the Cochrane analysis report statistically significant efficacy for prophylaxis, although they do not appear to have acknowledged this yet. There are currently 4 prophylaxis RCTs, and all 4 show statistically significant efficacy of ivermectin. Cochrane ignored them by simply choosing to only include post-exposure prophylaxis RCTs, even though they were included for the paxlovid analysis with many of the same authors. At the time there were no post-exposure RCTs and they knew that including any one of the 3 pre-exposure prophylaxis RCTs would show statistically significant efficacy.

This is the 46th of 53 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.000000087.

This is the 96th of 106 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001.

Important missing comments or errors? Let us know.

risk of high viral load, 96.0% lower, RR 0.04, p < 0.001, treatment 4 of 200 (2.0%), control 99 of 199 (49.7%), NNT 2.1.

risk of case, 71.6% lower, RR 0.28, p < 0.001, treatment 30 of 200 (15.0%), control 105 of 199 (52.8%), NNT 2.6, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Desort-Henin et al., 5 Jan 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Bulgaria, preprint, 5 authors, study period March 2022 - October 2022, dosage 200μg/kg day 1, 100μg/kg days 2-28, trial NCT05305560 (history) (SAIVE).

This Paper Ivermectin All

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0